Dynamics of laboratory markers of endothelial dysfunction in patients with psoriatic arthritis under the influence of the interleukin-17A inhibitor netakimab
Objective: a comparative evaluation of the effect of the interleukin-17A inhibitor (iIL) netakimab (NTK) and methotrexate (MTX) on laboratory markers of endothelial dysfunction in patients with psoriatic arthritis (PsA) in comparison with the dynamics of clinical efficacy indicators during 6 months...
Saved in:
| Main Authors: | A. V. Petrov, O. A. Pritulo, A. A. Petrov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2024-12-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1668 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study
by: T. V. Korotaeva, et al.
Published: (2020-11-01) -
Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study
by: T. V. Korotaeva, et al.
Published: (2021-03-01) -
Netakimab for the treatment of psoriatic arthritis: 3-year results of the phase III BCD-085-8/PATERA study
by: T. V. Korotaeva, et al.
Published: (2024-08-01) -
Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new?
by: Т. V. Korotaeva
Published: (2021-04-01) -
Methotrexate in a psoriatic arthritis patient
by: K. V. Aleksanyan, et al.
Published: (2016-09-01)